CLYM21088 / ANHL1931 / Casulo
Basic Study Information
Purpose:Location: University of Rochester
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus
chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal
B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab,
may help the body's immune system attack the cancer, and may interfere with the ability
of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined
with an immunotherapy called rituximab. Chemotherapy drugs work in different ways
to stop the growth of cancer cells, either by killing the cells, by stopping them
from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody.
It binds to a protein called CD20, which is found on B cells (a type of white blood
cell) and some types of cancer cells. This may help the immune system kill cancer
cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL.
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search